Cara Therapeutics' low P/S ratio reflects its declining reve...
Cara Therapeutics' low P/S ratio reflects its declining revenues and bleak future growth projection. Per investors, the company's future may not yield a significant revenue improvement.
Lacklustre Performance Is Driving Cara Therapeutics, Inc.'s (NASDAQ:CARA) 30% Price Drop
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment